A new PDUFA target date is April 30, 2025. The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for STS101 (dihydroergotamine [DHE] nasal ...

Migraine is a common neurological syndrome that affects approximately 10–20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the ...

Migraine medications fall into two broad categories ... makes it more tolerable for people who are prone to the nausea and vomiting that can sometimes accompany other medications. It is taken as a ...

aDanish Headache Center and Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark Migraine is the most common neurological disorder, and ...

It helps head off migraines by tightening blood vessels in the brain and preventing the release of substances that cause swelling. It can be injected subcutaneously, usually in the thigh well above ...

A recent study at Kansas State University – presented at the American Association of Bovine Practitioners Conference in Columbus, Ohio -- demonstrated how lidocaine-infused castration bands can help ...

Read on for her answers to frequently asked questions about migraine and menopause. The changes that occur during menopause are called perimenopause. During perimenopause, there are ups and downs ...

STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma's proprietary nasal delivery device.